Organization
Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China
11 abstracts
Abstract
Phase Ib study of a high potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced solid tumors.Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, China, The First Hospital of Jilin University, Changchun, Jilin Province, China, Shanghai Jiatan Pharmatech CO., LTD., Shanghai, Shanghai, China, Shanghai Jiatan Pharmatech CO., LTD., Shanghai, China,
Abstract
A phase II study of anlotinib plus albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or peritoneal carcinomar (A-Plus trial): Updated efficacy and safety.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,
Abstract
Study on the efficacy and toxicity of pamiparib combined with tamoxifen in the treatment of patients with epithelial ovarian cancer with biochemical recurrence during first-line PARPi maintenance therapy.Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma,
Abstract
Prevalence of HER-2 expression and correlation with clinicopathological features in gynecological cancer: A single-center retrospective study in China.Org: Chongqing University Cancer Hospital, Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, Affiliated Cancer Hospital of Chonqing University,
Abstract
Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer: A single-arm, prospective phase II trial.Org: Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China, Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China,
Abstract
Early detection, clinicopathological subtyping and prognosis prediction for patients with endometrial cancer using fragmentoimcs-based liquid-biopsy assay.Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Predictive value of C reactive protein (CRP) and D-dimer in patients with advanced cervical cancer treated with sintilimab and anlotinib.Org: Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Clinical Oncology School of Fujian Medical University, Fuzhou University,
Abstract
Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Collaborative Innovation Center for Cancer Medicine,
Abstract
BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.Org: APHP-INSERM U1149 Universite Paris Diderot, European Georges Pompidou Hospital, Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université,
Abstract
A combination of niraparib plus anlotinib in patients with platinum-resistant ovarian clear cell carcinoma: Results of a single-arm phase II study (CC-ANNIE study).Org: Sun Yat-Sen Memorial Hospital, Guangzhou JOYO Pharma, China National Biotec Group, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China,
Abstract
Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).Org: Centre François Baclesse, GINECO-Centre Jean Perrin, Clermont-Ferrand, France, Centre Léon Bérard, Hospital Universitario Reina Sofia de Cordoba, GEICO,